Multiple Myeloma Phase 2 Study Carfilzomib Report for Patients Like You

Filter by:

All
Start typing to see suggestions

patients

Home > Community Treatment Reports and Side Effects > Multiple Myeloma Phase 2 Study Carfilzomib Treatment Report

You appear to have JavaScript disabled in your browser. PatientsLikeMe relies on JavaScript and Cookies to deliver the best possible experience to you. How do I enable JavaScript?

What is Multiple Myeloma Phase 2 Study Carfilzomib?

NCT01402284 is a Phase 2, non-Randomized, open-label study of carfilzomib in combination with lenalidomide and dexamethasone in newly-diagnosed Multiple Myeloma. Carfilzomib is an experimental anti-cancer drug that has not yet been approved for treating multiple myeloma. Other Study IDs: 110221.

0 patients have reported taking Multiple Myeloma Phase 2 Study Carfilzomib .

Report created on May 28, 2012.